GEN Exclusives

More »

GEN News Highlights

More »
May 17, 2010

Merck & Co. Inks Partnership with ElexoPharm Focused on Cardiovascular Diseases

  • Merck & Co. is paying German CRO ElexoPharm €1.5 million up front as part of a collaboration and exclusive, worldwide licensing agreement to develop novel cardiovascular disease candidates that target aldosterone synthase. The partnership could bring ElexoPharm another €32.3 million in development, regulatory, and commercialization milestones plus royalties.

    Merck will be responsible for all development, regulatory, and commercialization activities relating to any products licensed through the deal.

    In addition to its core CRO business ElexoPharm is also undertaking in-house development of drugs that inhibit aldosterone synthase, or the CYP11B2 enzyme, for the potential treatment of congestive heart failure, myocardial fibrosis and hyperaldosteronism. CYP11B2 is a key enzyme in mineralocorticoid biosynthesis and catalyzes the conversion of deoxycorticosterone to the most potent mineralocorticoid aldosterone, ElexoPharm explains.

    The enzyme is regulated by several physiological parameters including the renin-angiotensin-aldosterone-system and plasma potassium concentrations. The firm has developed a preclinical portfolio of selective nonsteroidal CYP11B2 inhibitors, which it claims have no effect on other steroidogenic CYP enzymes and reduced ACTH-stimulated aldosterone levels in rats.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?